Media center

At PATH, our global health experts are developing partnerships, new devices, and solutions to the world's most pressing health needs. Contact us to speak with one of PATH's experts today.

Contact Us

Director of Global Strategic Communications:
David Verga

Email: media@path.org

PATH is advancing health equity around the world

June 7, 2024
Medical oxygen in the spotlight: What can be done to improve access for good?
May 30, 2024
A day with co-creators exhibiting inclusive innovation in Kenya
May 29, 2024
Lessons from Malawi's collaborative approach to digital health

Stay informed with PATH Insights

Featured Press Coverage

February 8, 2024
Good intentions, bad outcomes: The dangers of donated medical devices
Devex
April 18, 2024
Millions of Girls in Africa Will Miss HPV Shots After Merck Production Problem
The New York Times
February 12, 2024
Could new vaccines end malaria in Africa?
Al Jazeera

Recent Press Coverage

  1. Impact of public debt and low tax revenues on health and immunisation
    PATH’s Esther Nasikye speaks with Newzroom Afrika about the need for increased domestic financing for immunization and health programs in African countries.
    Published: February 2024
  2. Could new vaccines end malaria in Africa?
    After decades of research and development by PATH, GlaxoSmithKline, and other partners, the first doses of the RTS,S malaria vaccine began reaching children in Cameroon earlier this year.
    Published: February 2024
  3. Good intentions, bad outcomes: The dangers of donated medical devices
    COVID-19 spurred an increase in gifted medical devices, but the donations have left some facilities in under-resourced countries overwhelmed. PATH experts explain how too many facilities often lack training to use the equipment or funding to maintain it.
    Published: February 2024
  4. WHO grants prequalification to innovative polio vaccine, nOPV2, as nearly 1 billion doses are administered
    The World Health Organization granted prequalification to the novel oral polio vaccine type 2 (nOPV2), an innovative vaccine developed by a consortium of experts including PATH.
    Published: January 2024
Previous
Next

We develop evidence-based expertise and resources

Our global team leverages data and evidence to develop resources and innovations that bring good health to more people.

Explore our evidence

Join the latest discussions on health equity.

We partner with the public and private sector, government, and academia from around the world to share insightful conversations on the latest topics affecting health equity.

Explore PATH events

PATH Newsroom

Related articles

Read our latest

971 Item s
971 Item s
    Date
    From
    To
  1. PATH as a major sub-partner for USAID-funded STRIDES Activity
    PATH, as a major sub-partner on the consortium led by FHI360, launches the STRengthening Infectious disease DEtection Systems (STRIDES) Activity: a new Activity funded by USAID to combat epidemics, pandemics, and novel infectious disease threats.
    Published: November 2024
    Press Release
  2. PATH e Bio-Manguinhos/Fiocruz firmam compromisso para impulsionar plataformas tecnológicas e aumentar a produção local
    Published: October 2024
    Announcement
  3. PATH shares topline results from a Phase 3 study of an injectable rotavirus vaccine candidate
    The trial aimed to determine how well a new, injectable, non-replicating rotavirus vaccine candidate works, compared to a licensed oral rotavirus vaccine in preventing infant diarrhea.
    Published: October 2024
    Announcement
  4. PATH and Bio-Manguinhos/Fiocruz commit to boosting technological platforms and increasing local production
    Published: October 2024
    Announcement
  5. Unitaid and partners launch first-of-its-kind regional manufacturing initiative to improve access to medical oxygen in sub-Saharan Africa
    Published: October 2024
    Press Release
Next